CLINICAL TRIALS AND OBSERVATIONS Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
نویسندگان
چکیده
1Centre René Gauducheau, Nantes/St Herblain, France; 2Universita di Torino, Torino, Italy; 3Dana-Farber Cancer Institute, Boston, MA; 4Praxisklinik Dr Schlag, Würzburg, Germany; 5University of Athens, School of Medicine, Athens, Greece; 6Rabin Medical Center, Petah-Tiqva, Israel; 7University of Münster, Münster, Germany; 8Belgian Myeloma Study Group, Brussels, Belgium; 9Institute of Hematology and Medical Oncology “Seràgnoli,” University of Bologna, Bologna, Italy; 10Moscow Region Clinical Institute, Moscow, Russia; 11Department of Hematology, University of Medical Sciences, Poznan, Poland; 12Hospital Universitario Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain; 13Millennium Pharmaceuticals Inc, Cambridge, MA; 14Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, United Kingdom; 15Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ; and 16Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan- prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito,1 Massimo Gentile,1 Carla Mazzone,1 Davide Rossi,2 Francesco Di Raimondo,3 Sara Bringhen,4 Roberto Ria,5 Massimo Offidani,6 Francesca Patriarca,7 Chiara Nozzoli,8 Maria Teresa Petrucci,9 Giulia Benevolo,10 Iolanda Vincelli,11 Tommasina Guglielmelli,12 Mariella Grasso,13 Roberto Marasca,14 Luca Baldini,15 Vittorio Montefusco,16 Pellegrino Musto,17 Nicola Cascavilla,18 Ignazio ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
1Divisione di Ematologia dell’Università di Torino, Azienda Ospedaliera (AO) S. Giovanni Battista, Turin, Italy; 2Ematologia, Azienda Ospedaliera San Giovanni Battista, Turin, Italy; 3Divisione di Ematologia, Ospedale Centrale, Bolzano, Italy; 4Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy; 5Divisione di Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera Cervello, ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
We compared the efficacy of intensified chemotherapy followed by myeloablative therapy and autologous stem cell rescue with intensified chemotherapy alone in patients newly diagnosed with multiple myeloma. There were 261 eligible patients younger than 66 years with stage II/III multiple myeloma who were randomized after remission induction therapy with vincristine, adriamycin, dexamethasone (VA...
متن کاملCLINICAL TRIALS AND OBSERVATIONS High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
This prospective study evaluated the risk of arterial thrombosis in 195 consecutive patients aged 18 to 65 years with newly diagnosed multiple myeloma (MM). All patients were treated with 3 cycles of VAD (vincristine, doxorubicin, and dexamethasone) or TAD (thalidomide-AD) or PAD (bortezomib-AD) in national trials, followed by high-dose melphalan and autologous stem cell transplantation. For a ...
متن کاملBrief Report CLINICAL TRIALS AND OBSERVATIONS A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
In amyloid light chain (AL) amyloidosis, clonal plasma cells use proteasomes to cope with misfolded light chain-induced proteotoxicity, and theproteasome inhibitor bortezomib is a potential targeted therapy. Early reports supported this expectation, showing high response rates, particularly upfront. A prospective trial showed that single-agent bortezomib ishighlyand rapidlyeffective.Combination...
متن کامل